DUAL SOURCE PHOTON COUNTING CT
THE DIFFERENCE BETWEEN SEEING A CORONARY ARTERY AND UNDERSTANDING THE DISEASE OF THE PATIENT
Looking at coronary arteries with conventional CT is difficult, especially when there calcifications, stents, difficult heart rates, large patients.
And often non experienced operators tend to be a little sloppy in defining stenosis YES/NO, disease YES/NO, and so forth.
We use Dual Source Photon Counting CT for what it is.
A new imaging modality that allows to go deep into the finest details of coronary artery disease, beyond binary and oversimplified approaches.
We look for what is the specific disease features of the individual patient.
Beyond stenosis, into atherosclerotic plaques.
What kind plaque?
What kind of plaque features?
What risk of actual events in that specific individual?
The clinical impact is individualized diagnosis and therapy.
The diagnosis is different. The clinical decision is different.
Different approach.
Different reasoning.
Different journey for us and patients.
Better care.
Dr. Filippo Cademartiri & Dr. Erica Maffei
Experts in Photon Counting CT and Cardiovascular Imaging
- CDI/Centro Diagnostico Italiano, MILAN, Via Saint Bon, Italy
- SYNLAB IRCCS SDN, NAPLES, via Gianturco, Italy
@ironDPC Excellent post! One small refinement: LDL isn’t the only player on the court. Lp(a) and remnant lipoproteins can also initiate atherosclerosis. The common denominator is the retention of ApoB-containing particles in the arterial wall. No ApoB, no atherosclerosis CC @markkaplan20
@mikefoley Mike, I think I’m still 25 mentally. Unfortunately, my body has retained a very competent legal team that regularly challenges this assertion.
Just had my annual skin check, and my dermatologist pronounced my skin healthy. No biopsies, no scans, no referrals, no additional tests.
At 70, a successful doctor’s appointment is one that doesn’t generate three more doctor’s appointments.
My LinkedIn post about my photon-counting CT scan in Milan with @FCademartiri has 43,000 views and counting. Apparently, my coronary arteries are more popular than the rest of me! The comments are worth reading too.
https://t.co/hsURoaxF0j
@HWein68@FCademartiri@TimAFischellMD describes the “oculostenotic reflex” in the foreword to my book. Given my earlier CCTA showing >70% stenosis and FFRct of 0.69, I suspect there was a substantial chance I'd have received a stent once in the cath lab. We'll never know.
@HWein68 Ah man, I’m really sorry to hear that. Conventional CCTA can overestimate stenosis due to calcium blooming artifacts. In my case, photon-counting CT by @FCademartiri measured my LAD stenosis at 48% versus 72% on conventional CCTA. Imaging precision matters.
Last month, I traveled to Milan to undergo photon-counting CT with @FCademartiri. His message resonates deeply with my own CVD journey: We've spent decades focusing on the narrowing of arteries rather than the disease within their walls. It's time to change the paradigm.
WHERE IS THE REAL CARDIOVASCULAR RISK?
PHOTON-COUNTING CT: SEE IT. MEASURE IT. UNDERSTAND IT.
For decades, we've been predicting a disease we couldn't properly see.
Risk factors. Risk scores. Ischemia. Stenosis. FFR. LVEF.
All important.
BUT NONE OF THEM IS ATHEROSCLEROSIS.
Risk factors predict probabilities. Functional parameters describe consequences.
But patients are not statistics. And stenosis is not the disease.
Two patients with identical risk profiles can have dramatically different atherosclerotic burdens and plaque phenotypes.
Cardiac CT changed the game. Photon-Counting CT is taking it further.
We can SEE the disease. MEASURE its burden. CHARACTERIZE its phenotype.
So why are we still thinking primarily in terms of proxies and surrogates?
Why not start from the actual disease and use risk factors, physiology, and biomarkers to understand and manage it?
Treat the atherosclerosis. Target its drivers. Explain the disease to the patient.
Not just the probability of developing it.
RISK FACTORS ARE NOT THE DISEASE.
STENOSIS IS NOT THE DISEASE.
ATHEROSCLEROSIS IS.
Perhaps cardiovascular medicine needs less obsession with predicting what we can already see.
AND MORE COURAGE TO CHANGE THE WAY WE THINK.
Very interesting study, but the headline overstates what the research actually demonstrates. A few important points:
This was an observational study, not a randomized controlled trial. As the authors explicitly acknowledge, “the results do not imply causality and should be considered exploratory.”
The study population had symptomatic stable angina, not asymptomatic coronary artery disease.
Some 26% of the completely revascularized patients underwent bypass surgery. This is not a study of stents versus optimal medical therapy.
Procedural heart attacks were excluded from the endpoint, potentially overlooking an important downside of revascularization demonstrated in ISCHEMIA.
Statin adherence was significantly higher in the completely revascularized group (93% vs. 82%). While the researchers adjusted for this, I’d be particularly interested in achieved LDL-C and ApoB levels.
Beyond three years, the difference between complete and incomplete revascularization was no longer statistically significant (HR 1.98, p=0.09).
The findings are intriguing and certainly warrant further investigation. But demonstrating that an untreated flow-limiting stenosis is associated with increased cardiovascular risk is not the same as demonstrating that stenting that stenosis reduces overall cardiovascular risk compared with aggressive medical therapy.